- Home
- KZIA vs PSTV Comparison
KZIA vs PSTV Comparison
Compare KZIA & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- PSTV
- Stock Information
- Founded
- KZIA 1994
- PSTV 1996
- Country
- KZIA Australia
- PSTV United States
- Employees
- KZIA N/A
- PSTV N/A
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- PSTV Medical/Dental Instruments
- Sector
- KZIA Health Care
- PSTV Health Care
- Exchange
- KZIA Nasdaq
- PSTV Nasdaq
- Market Cap
- KZIA 7.8M
- PSTV 6.3M
- IPO Year
- KZIA 1999
- PSTV N/A
- Fundamental
- Price
- KZIA $1.42
- PSTV $1.17
- Analyst Decision
- KZIA Strong Buy
- PSTV Strong Buy
- Analyst Count
- KZIA 1
- PSTV 2
- Target Price
- KZIA $20.00
- PSTV $13.50
- AVG Volume (30 Days)
- KZIA 116.4K
- PSTV 38.1K
- Earning Date
- KZIA 11-15-2024
- PSTV 03-04-2025
- Dividend Yield
- KZIA N/A
- PSTV N/A
- EPS Growth
- KZIA N/A
- PSTV N/A
- EPS
- KZIA N/A
- PSTV N/A
- Revenue
- KZIA $1,655,324.00
- PSTV $5,725,000.00
- Revenue This Year
- KZIA $806.89
- PSTV $32.12
- Revenue Next Year
- KZIA N/A
- PSTV N/A
- P/E Ratio
- KZIA N/A
- PSTV N/A
- Revenue Growth
- KZIA 248000.00
- PSTV 52.63
- 52 Week Low
- KZIA $1.39
- PSTV $0.93
- 52 Week High
- KZIA $15.80
- PSTV $2.67
- Technical
- Relative Strength Index (RSI)
- KZIA 20.74
- PSTV 47.54
- Support Level
- KZIA $1.42
- PSTV $1.12
- Resistance Level
- KZIA $1.89
- PSTV $1.24
- Average True Range (ATR)
- KZIA 0.24
- PSTV 0.08
- MACD
- KZIA 0.02
- PSTV 0.01
- Stochastic Oscillator
- KZIA 1.40
- PSTV 30.77
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
About PSTV PLUS THERAPEUTICS Inc.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).